CHERRYL PURVIS: Open Payments
NPI 1386772283 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$888 in 49 payments from 15 companies in 2025. Trend: 2023 $872 · 2024 $911 · 2025 $888
Food & beverage: $888
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $248 |
| Abbott Laboratories | 8 | $154 |
| Sumitomo Pharma America, Inc. | 9 | $143 |
| GlaxoSmithKline, LLC. | 5 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| ABBVIE INC. | 2 | $39 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 2 | $19 |
| Lundbeck LLC | 1 | $18 |
Products named: FREESTYLE LIBRE, GEMTESA, FARXIGA, AIRSUPRA, TRELEGY ELLIPTA, REXULTI, UBRELVY, Kerendia.
Industry payments across MS — which companies pay providers there.
